Inactive Instrument

Highlights Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, vs. Street Est of $17.7M	05-08	MT
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	03-07	MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	03-07	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-07	CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	02-22	MT
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	01-05	CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	12-21	CI
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults	11-28	CI
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis	11-27	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket	11-15	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges	11-14	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $45.1M, vs. Street Est of $15.9M	11-14	MT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Wins Additional Financial Grants from Japanese Government	04/10/23	CI
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis	26/09/23	CI
Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19	05/09/23	CI
Arcturus Therapeutics Says Arcalis Joint Venture Received $115 Million in Grants From Japanese Government	14/08/23	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q2 Revenue $10.5M, vs. Street Est of $49.3M	07/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

Highlights

Filters